Companies Dominating the Nuclear Medicine Landscape
- GE Healthcare
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Jubilant Pharmova Limited
- Nordion (Canada), Inc.
- Bracco Imaging S.P.A
- The Institute for Radioelements (IRE)
- NTP Radioisotopes SOC Ltd.
- The Australian Nuclear Science and Technology Organization (ANSTO)
- Mallinckrodt Pharmaceuticals
- Lantheus
- Eckert & Ziegler
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of nuclear medicine is estimated at USD 14.78 billion.
The global nuclear medicine market is likely to rise from USD 12.94 billion in 2024 to USD 143.02 billion by 2037, exhibiting a CAGR of around 20.3% during the forecast timeline, between 2025 and 2037.
Asia Pacific industry is likely to hold largest revenue share by 2037, owing to increasing awareness about nuclear medicine and growing investment in nuclear medicine space in the region.
The major players in the market include GE Healthcare, Jubilant Pharmova Limited, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization (ANSTO), Mallinckrodt Pharmaceuticals, Lantheus, Eckert & Ziegler.
